Zhuhai Rundu Pharmaceutical Co., Ltd. announced its participation in the 12th National Centralized Drug Procurement. Its Diclofenac Sodium Sustained-Release Tablets (75mg and 100mg) were selected. This is expected to increase sales and market share, enhancing brand influence. The company will closely monitor developments and inform investors of risks.
Summary generated by AI · Always verify with source document
Securities Code: 002923
Securities Abbreviation: Rundu Pharmaceutical
Announcement No.: 2026-057
Zhuhai Rundu Pharmaceutical Co., Ltd.
Announcement on Company Products Selected in the 12th National Centralized Drug Procurement
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.